Status:
COMPLETED
Leflunomide in Systemic Lupus Erythematosus
Lead Sponsor:
Sanofi
Conditions:
Systemic Lupus Eythematosus (SLE)
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
A pilot study to evaluate the efficacy and safety of leflunomide in SLE patients with active disease who are refractory to cyclophosphamide
Eligibility Criteria
Inclusion
- Fulfill the revised ACR criteria for SLE with either evidence of active disease according to SLE Disease Activity Index (SLEDAI)
Exclusion
- Patients who are pregnant or nursing women, or those with life threatening disease
- The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Key Trial Info
Start Date :
January 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2004
Estimated Enrollment :
27 Patients enrolled
Trial Details
Trial ID
NCT00637819
Start Date
January 1 2003
End Date
July 1 2004
Last Update
March 28 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sanofi-Aventis
Hong Kong, Hong Kong